Clinical Trial Update: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) [Phase 3]

View source ↗

Summary

Phase III trial evaluating 177Lu-PSMA-617 plus standard of care versus standard of care alone in metastatic hormone-sensitive prostate cancer (mHSPC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Prostate Cancer
• Prostate Cancer

Drugs mentioned

• 177Lu-PSMA-617 (Lutetium-177 PSMA-617)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Prostatic Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING